CD133-Dependent Activation of Phosphoinositide 3-Kinase /AKT/Mammalian Target of Rapamycin Signaling in Melanoma Progression and Drug Resistance - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Cells Année : 2024

CD133-Dependent Activation of Phosphoinositide 3-Kinase /AKT/Mammalian Target of Rapamycin Signaling in Melanoma Progression and Drug Resistance

Naji Kharouf
Thomas W. Flanagan
  • Fonction : Auteur
Abdulhadi A. Alamodi
  • Fonction : Auteur
Youssef Al Hmada
  • Fonction : Auteur
Sofie-Yasmin Hassan
  • Fonction : Auteur
Hosam Shalaby
  • Fonction : Auteur
Simeon Santourlidis
  • Fonction : Auteur
Sarah-Lilly Hassan
  • Fonction : Auteur
Youssef Haikel
  • Fonction : Auteur
  • PersonId : 1098577
Mossad Megahed
  • Fonction : Auteur
Robert T. Brodell
  • Fonction : Auteur
Mohamed Hassan
  • Fonction : Auteur

Résumé

Melanoma frequently harbors genetic alterations in key molecules leading to the aberrant activation of PI3K and its downstream pathways. Although the role of PI3K/AKT/mTOR in melanoma progression and drug resistance is well documented, targeting the PI3K/AKT/mTOR pathway showed less efficiency in clinical trials than might have been expected, since the suppression of the PI3K/mTOR signaling pathway-induced feedback loops is mostly associated with the activation of compensatory pathways such as MAPK/MEK/ERK. Consequently, the development of intrinsic and acquired resistance can occur. As a solid tumor, melanoma is notorious for its heterogeneity. This can be expressed in the form of genetically divergent subpopulations including a small fraction of cancer stem-like cells (CSCs) and non-cancer stem cells (non-CSCs) that make the most of the tumor mass. Like other CSCs, melanoma stem-like cells (MSCs) are characterized by their unique cell surface proteins/stemness markers and aberrant signaling pathways. In addition to its function as a robust marker for stemness properties, CD133 is crucial for the maintenance of stemness properties and drug resistance. Herein, the role of CD133-dependent activation of PI3K/mTOR in the regulation of melanoma progression, drug resistance, and recurrence is reviewed.

Mots clés

Domaines

Cancer
Fichier principal
Vignette du fichier
islandora_170110.pdf (4.7 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04507103 , version 1 (15-03-2024)

Identifiants

Citer

Naji Kharouf, Thomas W. Flanagan, Abdulhadi A. Alamodi, Youssef Al Hmada, Sofie-Yasmin Hassan, et al.. CD133-Dependent Activation of Phosphoinositide 3-Kinase /AKT/Mammalian Target of Rapamycin Signaling in Melanoma Progression and Drug Resistance. Cells, 2024, 13 (3), pp.240. ⟨10.3390/cells13030240⟩. ⟨hal-04507103⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More